Annoroad Gene Technology
PrivateLast Round
Private Equity
Oct 8, 2022
Est. Valuation
$562.8M
Total Funding Raised
$156.83M
Company Overview
Annoroad Gene Technology operates in Healthcare & Life Sciences and is based in Beijing. Its latest recorded funding round was a Private Equity round in October 2022.
Annoroad Gene Technology is a biotechnology company that provides molecular-diagnostics-based IVD medical devices and multi-omics life sciences research services.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Biotech Equipment
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales, Usage-Based SaaS
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Annoroad Gene Technology Comparables
Compare Annoroad Gene Technology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Beijing Biomarker Technologies Co., Ltd. | 86% | |
| Genecast | 85% | |
| HaploX | 83% |
For institutional investors. Book with your work email.
Annoroad Gene Technology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Equity | Oct 8, 2022 | ||||
| Series C | Nov 2, 2017 | ||||
| Series B | Aug 4, 2015 | ||||
| Series A Extension | Feb 1, 2014 | ||||
| Series A | Dec 1, 2013 | ||||
Angel | Jun 22, 2012 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Annoroad Gene Technology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Biossom Investment Management | Series A Extension |
| Zhengxuan Investment | Angel |
| Northern Light Venture Capital | Series A Extension, Series A |
| DT Capital Partners | Series B |
| Ping An Ventures | Series C |
| China Renaissance Capital Investment | Series A |
| Shenzhen GTJA Investment Group | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 6, 2025
Grew 75% QoQ, from 16 to 28 employees.
For institutional investors. Book with your work email.
Annoroad Gene Technology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Annoroad Gene Technology's valuation, stock price, and market status.
Is Annoroad Gene Technology a public or private company?
Annoroad Gene Technology is a private company.
What is the current stock price of Annoroad Gene Technology?
Annoroad Gene Technology is a private company, so its shares have no public market price. Caplight tracks Annoroad Gene Technology's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Annoroad Gene Technology worth (valuation)?
Annoroad Gene Technology's valuation is estimated at $562.8M based on funding round data.
Can I buy Annoroad Gene Technology stock?
Annoroad Gene Technology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Annoroad Gene Technology's last funding round?
Annoroad Gene Technology's most recent funding round was Private Equity on October 8, 2022.
Who are the main investors in Annoroad Gene Technology?
Key investors in Annoroad Gene Technology include Ping An Ventures, Shenzhen GTJA Investment Group.
Will Annoroad Gene Technology IPO soon?
No public IPO plans have been announced for Annoroad Gene Technology.
How can I track Annoroad Gene Technology secondary market activity?
Caplight tracks bids, offers, and trades in Annoroad Gene Technology's shares on secondary markets.